Company Announcement / Press release Archives

Xspray publishes the final outcome of the rights issue

THIS PRESS RELEASE MAY NOT BE MADE PUBLIC, PUBLISHED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEELAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, SWITZERLAND, OR ANY OTHER JURISDICTION IN WHICH SUCH ACTIONS, WHOLLY OR IN PART, WOULD BE UNLAWFUL OR DEMAND ADDITIONAL REGISTRATION OR […]

Strong interest in Xspray Pharma AB’s rights issue – preliminary outcome is published

Xspray publishes prospectus relating to the rights issue

Interim Report Third Quarter 2024

July – September 2024, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -82,272 thousand (-38,942) Earnings per share before dilution amounted to SEK -2.44 (-1.59) Cash flow from operating activities amounted to SEK -41,275 thousand (-68,611) Cash flow from investing activities amounted to SEK -9,053 thousand (-14,470) January […]

Xspray resolves on a rights issue of approximately SEK 135 million and raises a loan of SEK 100 million

Xspray Pharma’s Nomination Committee for the Annual General Meeting 2025

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) publishes the Nomination Committee’s composition for the Annual General Meeting, May 13, 2025. The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on 21 May 2024, consists of: Thomas Eldered, appointed by Flerie AB, Chairman of the Nomination Committee Johan […]

Xspray Pharma Announces Positive FDA Meeting and Plans for Dasynoc NDA Resubmission

Stockholm, Sweden – September 19, 2024, Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY), a pharmaceutical company leveraging its proprietary HyNap™ technology to develop enhanced cancer therapies, today announced significant progress following a productive meeting with the U.S. Food and Drug Administration (FDA). The company plans to resubmit its New Drug Application (NDA) for Dasynoc in […]

Interim Report Second Quarter 2024

April–June 2024, Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -53,620 thousand (-51,402) Earnings per share before dilution amounted to SEK -1.64 (-2.27) Cash flow from operating activities amounted to SEK -64,181 thousand (-56,503) Cash flow from investing activities amounted to SEK -8,738 thousand (-16,027) Amounts in parentheses […]

Xspray Pharma Shares New Information on Dasynoc, a Novel CML Treatment in Development

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the New Drug Application (NDA) for Dasynoc, a novel treatment for chronic myeloid leukemia (CML) and acute lymphocytic leukemia (ALL). The updated NDA was sent to the FDA on January 31, 2024. […]

Xspray Pharma’s XS003 Study shows Matching Bioavailability to Tasigna at more than a 50% Lower Dose

Xspray Pharma provides an update on its second product candidate, XS003: New data shows matching bioavailability to Tasigna® at more than a 50% reduced dose. Stockholm, Sweden, July 9, 2024 – Xspray Pharma AB (Stockholm/Nasdaq: XSPRAY), a biotechnology company focused on developing improved protein kinase inhibitors (PKIs) for cancer treatment using its proprietary HyNap™ technology, […]